Natco Pharma (canada) Inc Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Natco Pharma (canada) Inc Pharmaceutical Import Records from India — 2 Products, $3.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Natco Pharma (canada) Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $3.8M Trade | TransData Nexus

Natco Pharma (canada) Inc

Pharmaceutical Importer · Canada · Antivirals Focus · $3.8M Total Trade · DGFT Verified

Natco Pharma (canada) Inc is a pharmaceutical importer based in Canada with a total trade value of $3.8M across 2 products in 2 therapeutic categories. Based on 79 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Natco Pharma (canada) Inc sources from 4 verified Indian suppliers, with Natco Pharma Limited accounting for 85.2% of imports.

Natco Pharma (canada) Inc — Import Portfolio & Supplier Network

Natco Pharma (canada) Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Natco Pharma (canada) Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Natco Pharma Limited	$968.1K	41	85.2%
Laurus Labs Limited	$109.4K	3	9.6%
Apex Laboratories Private Limited

What Formulations Does Natco Pharma (canada) Inc Import?

Formulation	Value	Ships
Tenofovir disoproxil fumarate	$100.0K	2
Nat-bendamustine 25MG injections appendix 4r rodtep entry no:10151other references ci no	$74.1K	2
Nat oseltamivir phosphate 75MG capsules10 s appendix 4r rodtep entry no 10153 other reference s ci no	$50.0K	1
Nat oseltamivir phosphate 30MG capsules10 s appendix 4r rodtep entry no 10153 other reference s ci no	$50.0K	1
Nat lanthanum carrbonate 1000MG tablets appen dix4r rodtep entry no 10153 other reference s ci no	$50.0K	1
Nat lanthanum carrbonate 750MG tablets appen dix4r rodtep entry no 10153 other reference s ci no	$50.0K	1
Nat-oseltamivir 45MG capsules 10's 45792x10'sappendix 4r rodtep entry no:10153other references ci no	$50.0K	1
Nat-oseltamivir 75MG capsules 10's 94752x10'sappendix 4r rodtep entry no:10153other references ci no	$50.0K	1
Nat-oseltamivir 75MG capsules 10's 94464x10'sappendix 4r rodtep entry no:10153other references ci no	$50.0K	1
Nat-oseltamivir 75MG capsules 10's 82848x10'sappendix 4r rodtep entry no:10153other references ci no	$50.0K	1
Nat-oseltamivir 75MG capsules 10's	$50.0K	1
Nat-oseltamivir 75MG capsules 10's 83232x10'sappendix 4r rodtep entry no:10153other references ci no	$50.0K	1
Nat apixaban 5 MG tablets 1000 s 1446 x1000 appendix 4r rodtep entry no 10153 other reference s ci no	$49.7K	1
Sanis imatinib 400 MG tablets 30 s 1500x 30 appendix 4r rodtep entry no 10112 other reference s ci no	$49.6K	1
Nat-bendamustine 25MG injections appendix 4r rodtep entry no:10151other references ci no	$38.0K	1

Natco Pharma (canada) Inc imports 46 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Oseltamivir	Antivirals	$3.8M	75	2.4%	2
2	Pomalidomide	Advanced Oncology	$64.3K	4	1.5%	7

Natco Pharma (canada) Inc imports 2 pharmaceutical products across 2 categories into Canada totaling $3.8M.

Natco Pharma (canada) Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Natco Pharma (Canada) Inc. is the Canadian subsidiary of Natco Pharma Limited, an Indian multinational pharmaceutical company established in 1981. Headquartered in Mississauga, Ontario, Natco Pharma (Canada) Inc. operates as a vertically integrated pharmaceutical company, focusing on research and development (R&D) and the manufacturing of drug products. The company is dedicated to increasing access to affordable medicines that meet the highest standards of quality, supply reliability, and customer service. (natcopharma.ca)

Natco Pharma Limited, the parent company, is renowned for its expertise in producing generic pharmaceuticals, particularly in oncology, cardiology, and diabetology. The Canadian subsidiary leverages this expertise to supply high-quality generic medicines to the Canadian market. By establishing a direct presence in Canada, Natco Pharma (Canada) Inc. aims to enhance its service offerings and strengthen its commitment to the Canadian healthcare system.

2Distribution Network

Natco Pharma (Canada) Inc. operates from its headquarters located at 2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario L5N 1P7. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic position in Mississauga provides advantageous access to major transportation routes, facilitating efficient distribution across Canada. This central location enables the company to effectively serve the Canadian market and manage its supply chain operations. (natcopharma.ca)

3Industry Role

In Canada's pharmaceutical supply chain, Natco Pharma (Canada) Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company, Natco Pharma Limited, and other suppliers, the subsidiary ensures the availability of high-quality generic medicines in the Canadian market. This role is crucial in providing cost-effective alternatives to brand-name drugs, thereby enhancing access to essential medications for Canadian patients.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Natco Pharma (canada) Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Natco Pharma (Canada) Inc. demonstrates a high degree of supplier concentration, with 85.2% of its imports sourced from Natco Pharma Limited. This single-source dependency indicates a strategic choice to maintain control over product quality and supply chain reliability. The substantial volume of imports from Natco Pharma Limited suggests a stable and long-term relationship, which is beneficial for ensuring consistent product availability and quality. However, this concentration also exposes the company to potential risks associated with over-reliance on a single supplier, such as supply disruptions or changes in pricing. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

The resilience of Natco Pharma (Canada) Inc.'s supply chain is closely tied to the stability and reliability of its primary supplier, Natco Pharma Limited. The company's reliance on a single supplier for the majority of its imports may pose challenges in the event of supply disruptions. To enhance supply chain resilience, it would be prudent for Natco Pharma (Canada) Inc. to consider establishing relationships with additional suppliers and diversifying its product formulations. This approach would provide alternative sources and reduce the impact of potential disruptions. Ensuring that all suppliers comply with Good Manufacturing Practices (GMP) and other regulatory standards is essential for maintaining product quality and safety.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the primary regulatory authority overseeing pharmaceutical imports is Health Canada. The Food and Drug Regulations govern the importation, sale, and distribution of pharmaceutical products, ensuring they meet safety, efficacy, and quality standards. For foreign manufacturers, including those in India, obtaining a Drug Establishment Licence (DEL) is mandatory to import drugs into Canada. Additionally, compliance with Good Manufacturing Practices (GMP) is required, and foreign manufacturing sites must be listed on the importer's DEL. (canada.ca)

2Import Licensing & GMP

Importers of pharmaceutical products into Canada must hold an Establishment Licence (EL) for the activity of importation. The foreign manufacturing site must be listed on the importer's EL. For Active Pharmaceutical Ingredients (APIs), importers are required to sign an attestation to demonstrate the GMP compliance status of the foreign buildings where fabrication, packaging/labeling, and/or testing occur. Health Canada uses these attestations as proof of GMP compliance for non-sterile APIs. (canada.ca)

3Quality & Labeling

Natco Pharma (canada) Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Natco Pharma (Canada) Inc. focuses on importing generic pharmaceuticals in the antiviral and advanced oncology therapeutic categories. The substantial import value of Oseltamivir indicates a strong market demand for antiviral medications, particularly during influenza seasons. The inclusion of Pomalidomide in the product portfolio suggests a strategic emphasis on oncology treatments, addressing the needs of patients requiring advanced cancer therapies. This product strategy aligns with the company's mission to increase access to affordable medicines that meet the highest standards of quality and reliability.

2Sourcing Profile

Natco Pharma (Canada) Inc. primarily sources generic drug formulations from its parent company, Natco Pharma Limited, and other suppliers. The focus on finished pharmaceutical formulations, rather than raw Active Pharmaceutical Ingredients (APIs), indicates a strategy to provide ready-to-use medications to the Canadian market. India's established pharmaceutical manufacturing capabilities and compliance with international regulatory standards make it a suitable source for these products.

3Market Positioning

Seller's Guide — How to Become a Supplier to Natco Pharma (canada) Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Natco Pharma (Canada) Inc., especially if they can offer products that complement the existing portfolio or meet unmet market needs. Gaps in the current sourcing include potential expansion into other therapeutic areas or the introduction of innovative formulations. Indian exporters with a strong track record of regulatory compliance and product quality may find it advantageous to approach Natco Pharma (Canada) Inc. to explore partnership opportunities.

2Requirements & Qualifications

Indian exporters seeking to supply Natco Pharma (Canada) Inc. and the Canadian market must ensure their products comply with Health Canada's regulatory requirements. This includes obtaining necessary certifications, adhering to GMP standards, and ensuring that manufacturing facilities are listed on the importer's Establishment Licence. Products must also meet labeling requirements in both English and French and comply with any serialization mandates. Demonstrating a commitment to quality and regulatory compliance is essential for establishing a successful partnership.

3How to Approach

Frequently Asked Questions — Natco Pharma (canada) Inc

What products does Natco Pharma (canada) Inc import from India?

Natco Pharma (canada) Inc imports 2 pharmaceutical products across 2 categories. Top imports: Oseltamivir ($3.8M), Pomalidomide ($64.3K).

Who supplies pharmaceuticals to Natco Pharma (canada) Inc from India?

Natco Pharma (canada) Inc sources from 4 verified Indian suppliers. The primary supplier is Natco Pharma Limited (85.2% of imports, $968.1K).

What is Natco Pharma (canada) Inc's total pharmaceutical import value?

Natco Pharma (canada) Inc's total pharmaceutical import value from India is $3.8M, based on 79 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Natco Pharma (canada) Inc focus on?

Natco Pharma (canada) Inc imports across 2 categories. The largest: Antivirals (98.3%), Advanced Oncology (1.7%).

Get Full Natco Pharma (canada) Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.